Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | PLD2 | O14939 | 1/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12012671 | 0.95 | PLD2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CCNT1 | |
| SCHEMBL1312238 | 0.95 | PLD2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CCNT1 | |
| SCHEMBL1312579 | 0.90 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4PLD2 | |
| SCHEMBL1311762 | 0.89 | KDM4E (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4PLD2 | |
| SCHEMBL1313566 | 0.89 | PLD2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4PLD2 | |
| SCHEMBL1312476 | 0.89 | PLD2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4PLD2 | |
| SCHEMBL1312652 | 0.87 | PLD2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4PLD2 | |
| SCHEMBL13363980 | 0.85 | PLD1 (0.43) | CCNT1CDK9PLD2PLD1MEN1 | |
| SCHEMBL17004616 | 0.85 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL1324968 | 0.84 | KDM4E (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | HTR2B, HTR1B, HTR3B | CHRNB2 261/4885CHRNB4 401/4885CHRNA3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.